Cargando…

Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort

BACKGROUND: Gene therapy shows promise as a potential “cure” for hemophilia A and B. Adeno‐associated virus (AAV) vectors are the leading platform to deliver modified genetic code of factor VIII or IX to the liver effecting endogenous production. Patient exposure to wild‐type AAV leads to the format...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyce, Sara, James, Izabela, Rangarajan, Savita, Curry, Nicola, Bagot, Catherine, Austin, Steven, Laffan, Mike, Mangles, Sarah, Chandrakumaran, Kandiah, Mundy, Carina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166283/ https://www.ncbi.nlm.nih.gov/pubmed/35677030 http://dx.doi.org/10.1002/rth2.12705

Ejemplares similares

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
por: Stanford, Sophia, et al.
Publicado: (2019)

RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
por: Boyce, Sara, et al.
Publicado: (2023)

HCV Genotypes of People with Hemophilia in Countries with High Seroprevalances
por: Mahlangu, J N, et al.
Publicado: (2011)

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
por: Fong, Sylvia, et al.
Publicado: (2022)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

An overview of the pathfinder clinical trials program: Long‐term efficacy and safety of N8‐GP in patients with hemophilia A
por: Matsushita, Tadashi, et al.
Publicado: (2020)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
por: Sun, Junjiang, et al.
Publicado: (2022)

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs
por: Kashiwakura, Yuji, et al.
Publicado: (2022)

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
por: Klamroth, Robert, et al.
Publicado: (2022)

Advances of adeno-associated virus applied in gene therapy to hemophilia from bench work to the clinical use
por: Pei, Xiaolei, et al.
Publicado: (2019)

Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus
por: Puetz, John
Publicado: (2023)

Educational needs of patients, families, and healthcare professionals to support the patient journey in haemophilia gene therapy in the UK
por: Boyce, Sara, et al.
Publicado: (2023)

Fear of cancer recurrence in peritoneal malignancy patients following complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): an observational study protocol
por: Taher, Rayan, et al.
Publicado: (2022)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2017)

Direct-to-consumer Marketing to People with Hemophilia
por: Kucab, Philip, et al.
Publicado: (2016)

Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy
por: Day, John W., et al.
Publicado: (2023)

Molecular Engineering of Adeno-Associated Virus Capsid Improves Its Therapeutic Gene Transfer in Murine Models of Hemophilia and Retinal Degeneration
por: Mary, Bertin, et al.
Publicado: (2019)

Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A
por: Greig, Jenny A., et al.
Publicado: (2022)

Early sepsis identification following cytoreductive surgery for peritoneal malignancy
por: Wilson, Darius Cameron, et al.
Publicado: (2020)

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States
por: Khatri, Arpana, et al.
Publicado: (2022)

Autism spectrum disorders in boys at a major UK hemophilia center: prevalence and risk factors
por: Bladen, Melanie, et al.
Publicado: (2022)

Adeno-Viren
por: Falke, Dietrich
Publicado: (2009)

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Establishing an online physical exercise program for people with hemophilia
por: Wagner, Barbara, et al.
Publicado: (2019)

Effectiveness of rehabilitation on pain and function in people affected by hemophilia
por: Scaturro, Dalila, et al.
Publicado: (2021)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Rational Engineering and Preclinical Evaluation of Neddylation and SUMOylation Site Modified Adeno-Associated Virus Vectors in Murine Models of Hemophilia B and Leber Congenital Amaurosis
por: Maurya, Shubham, et al.
Publicado: (2019)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Seroprevalence of Molluscum contagiosum Virus in German and UK Populations
por: Sherwani, Subuhi, et al.
Publicado: (2014)

Effectiveness of rehabilitation on pain and function in people affected by hemophilia: Erratum
Publicado: (2022)

Complications and Implant Survival of Total Knee Arthroplasty in People with Hemophilia
por: Rodriguez-Merchan, Emerito Carlos, et al.
Publicado: (2022)

Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
por: Teng, Wei-Jung, et al.
Publicado: (2023)

Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry
por: Palmer, Kieran, et al.
Publicado: (2022)

Equine seroprevalence of West Nile virus antibodies in the UK in 2019
por: Folly, Arran J., et al.
Publicado: (2020)

Adeno-associated virus receptor complexes and implications for adeno-associated virus immune neutralization
por: Large, Edward E., et al.
Publicado: (2023)

The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
por: St‐Louis, Jean, et al.
Publicado: (2022)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72lcnvds5ug29vs3rbm9rfm28v